Physician profile
Sandeep Kunwar
NPI 1760907505
$2,396.21
in general payments reported to CMS, 2019-2025
30 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.00 · 2022: $63.05 · 2023: $689 · 2024: $842 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $434.64 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.52 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $213.92 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $175.86 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $162.80 | 2023-2025 | Farxiga, Breztri |
| Medtronic, INC. | $129.78 | 2022-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $119.93 | 2024-2025 | |
| Amgen INC. | $98.19 | 2020-2025 | Tepezza |
| Glaxosmithkline, LLC. | $92.55 | 2023-2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $81.14 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $67.23 | 2023-2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $66.99 | 2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $49.36 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.97 | 2025 | Relistor |
| Dexcom, INC. | $45.28 | 2022-2023 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.87 | 2023-2025 | Zepbound, Mounjaro, Lyumjev |
| Abbvie INC. | $28.64 | 2024 | |
| Sumitomo Pharma America, INC. | $26.54 | 2025 | Gemtesa |
| Baxter Healthcare | $26.43 | 2023 | Hillrom - Life 2000 Ventilation System |
| Tandem Diabetes Care, INC. | $23.17 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Biotech, INC. | $23.08 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.43 | 2023 | Gattex |
| Ascensia Diabetes Care US INC. | $19.54 | 2024 | |
| Pfizer INC. | $19.39 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.12 | 2025 | Caplyta |
| Cequr Corporation | $16.73 | 2022 | |
| Kyowa Kirin, INC. | $16.26 | 2024 | Crysvita |
| Astellas Pharma US INC | $16.04 | 2020 | |
| Lundbeck LLC | $13.52 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $13.29 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Kunwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.